SPECIAL ISSUE I YEARBOOK 2019

THE POWER

OF PATIENTS

In a year of high profile scandals and drug recalls, patients have been making their voices heard

A new era of buyers clubs in the UK

Closing the curtain on animal testing

Costly consequences for Valsartan 

In association with

In association with

Drug patents: fit for purpose?

Non-hormonal menopause treatments

Revolutionise post transplant care

02/24/2024 12:08:18
  • Home | The power of patients
  • Scandinavian Health Company Insight
  • Scandinavian Health Ltd.
  • In this issue
  • NSF
  • Contents
  • Capsugel
  • Capsugel Company Insight
  • Christensella: the key to unlocking gut microbiome-based drug discovery?
  • Molnar Company Insight
  • Molnar-Institute
  • A costly oversight: the ongoing impact of the valsartan recall
  • Novo Nordisk Company Insight
  • Novo Nordisk
  • Where is the UK’s supply of Migraleve?
  • Dupont Pharmaceuticals
  • Discussing drug policy reform with psychedelics campaigner Amanda Feilding
  • LB Bohle Company Insight
  • LB Bohle
  • Charting the life and times of the EMA as it leaves London
  • Komtur Pharmaceuticals Company Insight
  • Komtur Pharmaceuticals
  • CBD: the myth, the magic and the real deal drugs
  • CBDepot Company Insight
  • CBDepot
  • In the age of AMR, does a nationalised drug company make sense? The case for and against
  • AtoZ-CRO Company Insight
  • AtoZ-CRO
  • How do cancer cells communicate and can it help us catch them?
  • HOF Sonderanlagenbau
  • HOF Sonderanlagenbau Company Insight
  • Buyers’ clubs: the first step toward universal UK access to Orkambi?
  • Sterigenics
  • Owen Mumford
  • Are we nearing the end of animal testing in pharma?
  • Zenatek
  • Barc Lab
  • A safer ride: the latest innovation in targeted cancer treatment
  • Abiogen Pharma
  • Mimotopes
  • Next issue
12/18/2019 00:00:00